Cardiosense appoints John Martin as CMO, enhancing AI-driven cardiac care and advancing regulatory efforts for innovative hemodynamic monitoring solutions.
The FDA’s IDE approval allows Presidio to initiate a randomized, controlled trial in the United States and Australia to evaluate the safety and efficacy of its ULF neuromodulation technology
